# BioNTech restructuring, oncology shift, revenue cut > Live situation record from CLSTR: https://clstr.news/situations/biontech-trims-workforce-and-leadership-as-covid19-vaccine-demand-dwindles > Updated: 2026-08-06T23:19:16.000Z. Sources: 34. Developments: 9. In August 2026 BioNTech further cut its 2026 revenue outlook to €1.6‑1.9 billion, confirming a Q2 net loss of €820.8 million and a 60 % drop in revenue to €105.6 million. Shares fell to €79.15, about 6 % below the 200‑day average, and Citigroup lowered its price target to $125 while keeping a buy rating. The supervisory board confirmed Guido Oelkers, former CEO of Swedish Orphan Biovitrum, will assume the chief‑executive role on 1 February 2027, succeeding co‑founder Ugur Şahin. Şahin and Özlem Türeci will leave operational duties by year‑end to launch an independent mRNA‑innovation venture in which BioNTech retains a minority stake. The firm reiterated its pivot to oncology, spotlighting late‑stage candidates BNT327 (Pumitamig) and BNT323, and said it holds a cash and liquid‑asset buffer of roughly €16.6 billion to fund the transition. It also announced the planned closure of the Idar‑Oberstein, Marburg and Tübingen sites by the end of 2027 and the winding down of Singapore operations in early 2027. The industrial union IGBCE urged a sale rather than closure of the Marburg plant, noting reported interest from Moderna. ## Claims - BioNTech reported a net loss of €820.8 million for Q2 2026. (corroborated by 8 sources) - Q2 2026 revenue was €105.6 million, down 59.5 % year‑on‑year. (corroborated by 8 sources) - BioNTech cut its 2026 revenue forecast to €1.6‑1.9 billion from €2.0‑2.3 billion. (corroborated by 8 sources) - Guido Oelkers will become BioNTech's CEO by 1 February 2027, succeeding co‑founder Ugur Sahin. (corroborated by 7 sources) - Co‑founders Ugur Sahin and Özlem Türeci will leave BioNTech's operational management by end‑2026 to start a separate mRNA‑innovation firm. (corroborated by 7 sources) - BioNTech plans to close sites in Idar‑Oberstein, Marburg and Tübingen by end‑2027 and to wind down its Singapore operations in early 2027. (corroborated by 7 sources) - BioNTech's oncology pipeline includes late‑stage candidate Pumitamig (BNT327) for lung and breast cancer. (corroborated by 5 sources) - BioNTech holds cash and liquid assets of approximately €16.6 billion. (corroborated by 4 sources) ## Timeline ### 2026-08-06: BioNTech slashes 2026 revenue outlook, reports loss and names Guido Oelkers as new CEO BioNTech cut its 2026 revenue forecast, posted a €820 m loss, and named Guido Oelkers as new CEO; the IGBCE union pushes for a sale of the Marburg site amid restructuring pressure. 2 sources. https://clstr.news/cluster/biontech-slashes-2026-revenue-outlook-reports-loss-and-names-guido-oelkers-as-new-ceo ### 2026-08-04: BioNTech cuts 2026 revenue outlook and reports €820 million Q2 loss BioNTech posted a €820 million Q2 loss, cut 2026 revenue guidance to €1.6‑1.9 bn, appointed Guido Oelkers as CEO, and is refocusing on oncology with a €16.6 bn cash buffer. 10 sources. https://clstr.news/cluster/biontech-posts-135-bn-loss-as-covid19-vaccine-demand-collapses ### 2026-07-11: BioNTech cuts 1,860 jobs, shifts focus to oncology pipeline BioNTech will cut up to 1,860 jobs and close several sites as it pivots to an oncology pipeline featuring two late‑stage candidates, while maintaining €16.8 bn in liquidity; investor Cathie Wood sold shares in 2 sources. https://clstr.news/cluster/biontech-cuts-1860-jobs-shifts-focus-to-oncology-pipeline ### 2026-07-06: BioNTech targets €500 million savings and site sales to fund oncology shift BioNTech plans €500 million in cost cuts, may sell up to four German sites, and will channel savings into its oncology pipeline, while Moderna watches. 2 sources. https://clstr.news/cluster/biontech-targets-500-million-savings-and-site-sales-to-fund-oncology-shift ### 2026-06-17: Moderna Eyes Purchase of BioNTech Plants as BioNTech Announces Facility Closures in Germany Moderna may buy BioNTech plants in Germany amid talks on government support, while BioNTech plans to close the Tübingen site, risking 750 jobs and sparking debate over a €300 million state investment. 6 sources. https://clstr.news/cluster/moderna-explores-purchase-of-biontech-plants-in-germany ### 2026-06-07: BioNTech targets FDA approval for BNT323 cancer therapy as oncology pipeline expands BioNTech aims to submit its BNT323 cancer drug to the FDA in 2026 after promising trial results, while its stock slides amid a strategic shift from Covid vaccines to an expanding oncology pipeline. 2 sources. https://clstr.news/cluster/biontech-targets-fda-approval-for-bnt323-cancer-therapy-as-oncology-pipeline-expands ### 2026-06-06: CureVac Tübingen site to close, two‑thirds of jobs slated for cut by end‑2026 CureVac’s Tübingen site will close by Dec 2026, cutting about two‑thirds of jobs. A state‑backed task‑force seeks to retain knowledge, while the works council criticises Biontech’s handling and notes limited re 3 sources. https://clstr.news/cluster/badenwrttemberg-plant-closures-threaten-hundreds-of-jobs ### 2026-05-23: Biontech faces union criticism over plant closures and job losses IG BCE accuses Biontech of opaque plant‑sale plans, threatening up to 1,860 jobs as the biotech shifts focus to oncology and founders depart. 8 sources. https://clstr.news/cluster/biontech-faces-union-criticism-over-unclear-sale-of-german-and-singapore-sites-risking-1900-jobs ### 2026-05-14: BioNTech announces major layoffs and founder departures as it pivots to oncology BioNTech plans plant closures, 1,860 layoffs and founder exits while shareholders back an oncology‑centric restructuring. 8 sources. https://clstr.news/cluster/biontech-announces-plant-closures-and-founder-exits-as-pandemic-demand-collapses --- Cite as: BioNTech restructuring, oncology shift, revenue cut. CLSTR, https://clstr.news/situations/biontech-trims-workforce-and-leadership-as-covid19-vaccine-demand-dwindles